Veravas has focused our R&D efforts to develop two novel COVID-19 testing solutions.
Neutralizing antibody test to detect and quantitate antibodies that potently neutralize SARS-CoV-2 by binding to its surface and blocking entry into a person’s cells. Our antibody test is being developed to support vaccine development and vaccine efficacy testing.
Saliva-based rapid antigen test to detect SARS-CoV-2 in only 10 minutes to determine if a person is infected and shedding virus. Our antigen test will be inexpensive, fast and easily scalable to over 30 million tests per month for both high throughout CLIA lab and point-of-care use.
COVID-19 Testing video
Rapidly captures potentially damaging interferences, allowing the cleaned sample to be reliably tested using existing methods
Rapidly captures low abundance biomarkers, allowing the enriched sample to be tested using existing methods
Detect the presence of an interference-causing substance in a sample
Pre-treat a sample to remove an interference-causing substance and rule in/out whether it is clinically significant
Veravas’ proprietary sample preparation technology enables the simple, efficient, and cost effective conditioning and characterization of specimens to manage and mitigate a number of known sample interferences prior to the subsequent enrichment of low abundance biomarkers using our 6C’s:
The number of people taking over-the-counter, high-dose biotin supplements for health and cosmetic reasons is growing 20% annually worldwide.1 Biotin-related testing interference is also rising, which puts patients at risk of misdiagnosis, inappropriate patient management,2 or adverse events.3
Rapidly screen samples to identify biotin levels greater than 15 ng/mLLearn More
Proprietary antibody for use as an alternative to anti-biotin antibodies and streptavidin-based reagentsLearn More
Our dedicated team can answer your questions and help you with biotin-interference issues.Contact Us